Cost-Saving Potential of Implementing Pharmaceutical Cost Containment for Cardiovascular Disease Outpatients at One of the Hospitals in Cimahi

DOI

10.2991/978-94-6239-762-0_11How to use a DOI?

Keywords

Cardiovascular Disease; Cost Reduction; Hospital; Outpatient; Pharmaceutical Cost Containment

Abstract

Cardiovascular disease (CVD) causes one-third of deaths in Indonesia. Utilisation of the Indonesian National Health Insurance Scheme (JKN) to cover CVD is increasing. Reducing CVD costs in hospitals requires appropriate interventions. This study aims to evaluate the potential cost savings for patients with the illness through various pharmaceutical cost containment measures. The research was conducted using a descriptive design with a retrospective approach. The sample used consisted of patients with cardiovascular disease in the outpatient unit who met the inclusion criteria for the period of September 11–15, 2023. Data were collected from medical records and patient financial summaries. This research involved 783 outpatients from a hospital in Cimahi during a five-day observation period. The most significant savings come from switching from branded to generic medications (28.74%), followed by the cost of drugs must be less than the standard JKN INA-CBG code of Q-5-44-0 in B-class government hospitals in Region 1 (4.79%) and conformity with The National Formulary (3.85%), Additionally, selecting and implementing strategies for managing drug costs necessitates that pharmacists consider both patient safety and the quality of service. Therefore, it is necessary to manage pharmaceutical costs using information technology to reduce them.

Copyright

© 2026 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits any noncommercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modified the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.

Download article (PDF)

TY  - CONF
AU  - Oskar Skarayadi
AU  - Dwi Endarti
AU  - Ali Ghufron Mukti
AU  - Satibi Satibi
AU  - Sjarifuddin Sjarifuddin
AU  - Rudi Dwi Laksono
PY  - 2026
DA  - 2026/09/04
TI  - Cost-Saving Potential of Implementing Pharmaceutical Cost Containment for Cardiovascular Disease Outpatients at One of the Hospitals in Cimahi
BT  - Proceedings of the 6th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BIOMIC 2025)
PB  - Atlantis Press
SP  - 163
EP  - 171
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6239-762-0_11
DO  - 10.2991/978-94-6239-762-0_11
ID  - Skarayadi2026
ER  -